MAP 2017 – Molecular Analysis for Personalised Therapy

ESMO 2018 Congress

Preceptorship Courses

Apply now to join one of our Preceptorship courses on Immuno-oncology, Lung Cancer and Ovarian Cancer

Workshops & Courses

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

Patient Guides

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

New indication concerns extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL

On 19 January 2016, the US Food and Drug Administration (FDA) approved
ofatumumab (Arzerra Injection, Novartis Pharmaceuticals Corporation) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukaemia (CLL).

Ofatumumab was previously approved for the treatment of previously untreated patients with CLL for whom
fludarabine-based therapy was considered inappropriate and also for patients with CLL refractory to fludarabine and
alemtuzumab.

This new approval was based on demonstration of an improvement in progression-free survival (PFS) in a randomised, open-label trial comparing ofatumumab to observation in patients whose disease had a complete or partial response after at least two lines of prior therapy.

A total of 474 patients were randomised (1:1) to ofatumumab (n=238) or observation (n=236). The median age was 64.5 years (range 33-87). Patients in the ofatumumab arm had received a median of 2 prior therapies (range 2-5). The investigator-assessed median PFS was 29.4 months and 15.2 months in the ofatumumab and observation arms, respectively (HR: 0.50, p< 0.0001).

The most common adverse reactions (greater than or equal to 10%) in patients treated with ofatumumab therapy were infusion reactions, neutropenia and upper respiratory tract infection. Thirty-three percent of patients treated with ofatumumab reported serious adverse reactions. The most common serious adverse reactions were pneumonia, pyrexia and neutropenia (including febrile neutropenia).

The recommended dose and schedule for ofatumumab therapy is 300 mg by intravenous infusion on day 1 followed by 1,000 mg on day 8 and then 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years.

This application was granted Priority Review. Full prescribing information is available
here.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a
form online, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).